DURHAM – Tellus Therapeutics, the neonatal care startup based in Durham, is raising a new round of funding and is almost halfway to its goal of $35 million.
That’s according to an SEC filing.
Tellus raised $35 million late last year as it continues in efforts to advance treatments for newborn children in neonatal intensive care unit.
According to the latest filing
Tellus landed $15,999,999 from a single investor.
Durham biotech startup Tellus secures $35M Series A to advance treatment for babies in the NICU
With $2M in hand, neonatal startup Tellus Therapeutics plans future raise
